On the other hand, it has been demonstrated that PI3K/Akt/mTOR inhibitors enhance radiosensitivity of radioresistant prostate cancer cells in part by downregulating proteins involved in HR (such as Rad51) and NHEJ (such as Ku70/Ku80) (Chang et al., 2014). The gene discussed is PIK3CA; the disease is prostate carcinoma.